SSP-004184
DrugAll subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
Other names: SPD602, FBS0701
NCT Number: NCT01732263
The purpose of this study is to evaluate how much of the study drug SSP-004184 (SPD602) is absorbed by the body and how long it takes to be eliminated from the body in healthy subjects and subjects with mild, moderate, and severe hepatic (liver) impairment compared with subjects with healthy normal liver function.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Clinical Pharmacology of Miami, Miami, Florida, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Subjects who do not have hepatic impairment (healthy subjects)
Subjects with hepatic impairment
Exclusion criteria
Subjects who do not have hepatic impairment (healthy subjects)
Subjects with hepatic impairment
All subjects
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
Other names: SPD602, FBS0701
Time frame: Over 96 hours post-dose
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Time frame: Over 96 hours post-dose
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.
Time frame: Over 96 hours post-dose
Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.
Time frame: Over 96 hours post-dose
The time it takes for the blood plasma concentration of a substance to halve.
Time frame: Over 96 hours post-dose
The rate at which a drug is removed from the body.
Time frame: Over 96 hours post-dose
The distribution of a medication between plasma and the rest of the body.
Shire
Industry
A Phase 1, Open-label, Single-dose Study of the Pharmacokinetics, Safety, and Tolerability of SSP-004184 (SPD602) in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03289234
Healthy, Hepatic Impairment
Fukuoka, Japan
View Trial DetailsNCT06908954
Healthy, Hepatic Impairment
Miami, Florida, United States
View Trial DetailsNCT05765344
Healthy, Hepatic Impairment
Lake Forest, California, United States
View Trial DetailsNCT04819464
Healthy, Hepatic Impairment
Kistarcsa, Hungary
View Trial Details